163 related articles for article (PubMed ID: 33821545)
1. Initial experience with subcutaneous depot buprenorphine in a medically supervised injecting facility.
Weeks A; Cogger S; Clark N
Drug Alcohol Rev; 2021 Nov; 40(7):1354-1355. PubMed ID: 33821545
[No Abstract] [Full Text] [Related]
2. Use and misuse of opioid replacement therapies: a Queensland study.
Smirnov A; Kemp R
Subst Use Misuse; 2012 Jan; 47(1):78-85. PubMed ID: 22216993
[TBL] [Abstract][Full Text] [Related]
3. Utilization of buprenorphine and methadone among opioid users who inject drugs.
Tsui JI; Burt R; Thiede H; Glick SN
Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
[TBL] [Abstract][Full Text] [Related]
4. The uptake of long-acting depot buprenorphine for treating opioid dependence in Australia, 2019-2022: longitudinal sales data analysis.
Lintzeris N; Hayes V; Dunlop AJ
Med J Aust; 2024 Apr; 220(6):339-340. PubMed ID: 38438113
[No Abstract] [Full Text] [Related]
5. Does the advent of depot therapy represent a step change in our understanding of opioid use disorder and its treatment?
Roberts E; Humphreys K
Drug Alcohol Rev; 2024 Jan; 43(1):261-264. PubMed ID: 37525510
[TBL] [Abstract][Full Text] [Related]
6. Availability of Extended-Release Buprenorphine to Treat Opioid Use Disorders Among Medicaid-Covered Patients.
Shover CL
Psychiatr Serv; 2021 Feb; 72(2):225-226. PubMed ID: 32907476
[No Abstract] [Full Text] [Related]
7. Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges.
Arunogiri S; Lintzeris N
J Subst Abuse Treat; 2021 May; 124():108221. PubMed ID: 33303254
[TBL] [Abstract][Full Text] [Related]
8. Illicit buprenorphine use, interest in and access to buprenorphine treatment among syringe exchange participants.
Fox AD; Chamberlain A; Sohler NL; Frost T; Cunningham CO
J Subst Abuse Treat; 2015 Jan; 48(1):112-6. PubMed ID: 25205666
[TBL] [Abstract][Full Text] [Related]
9. Time to include buprenorphine-naloxone combination in the WHO Model List of Essential Medicines.
Balhara YP
J Opioid Manag; 2013; 9(4):237. PubMed ID: 24380101
[No Abstract] [Full Text] [Related]
10. Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia.
Geddes L; Iversen J; Wand H; Maher L
Addiction; 2021 Mar; 116(3):525-535. PubMed ID: 32557931
[TBL] [Abstract][Full Text] [Related]
11. Prevention of Opioid Overdose.
Babu KM; Brent J; Juurlink DN
N Engl J Med; 2019 Jun; 380(23):2246-2255. PubMed ID: 31167053
[No Abstract] [Full Text] [Related]
12. Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings.
Dunlop AJ; White B; Roberts J; Cretikos M; Attalla D; Ling R; Searles A; Mackson J; Doyle MF; McEntyre E; Attia J; Oldmeadow C; Howard MV; Murrell T; Haber PS; Lintzeris N
Addiction; 2022 Feb; 117(2):382-391. PubMed ID: 34184798
[TBL] [Abstract][Full Text] [Related]
13. Differences in polysubstance use patterns and drug-related outcomes between people who inject drugs receiving and not receiving opioid substitution therapies.
Betts KS; Chan G; McIlwraith F; Dietze P; Whittaker E; Burns L; Alati R
Addiction; 2016 Jul; 111(7):1214-23. PubMed ID: 26857811
[TBL] [Abstract][Full Text] [Related]
14. Buprenorphine for Persons on Waiting Lists for Treatment for Opioid Dependence.
Yan K
N Engl J Med; 2017 Mar; 376(10):1000. PubMed ID: 28276662
[No Abstract] [Full Text] [Related]
15. Buprenorphine for Persons on Waiting Lists for Treatment for Opioid Dependence.
Sigmon SC; Schwartz RP; Higgins ST
N Engl J Med; 2017 Mar; 376(10):1000-1001. PubMed ID: 28273017
[No Abstract] [Full Text] [Related]
16. Medication-Based Treatment to Address Opioid Use Disorder.
Leshner AI; Dzau VJ
JAMA; 2019 Jun; 321(21):2071-2072. PubMed ID: 31046072
[No Abstract] [Full Text] [Related]
17. Enhancing engagement between legislators and nursing to increase buprenorphine access.
Finnell DS; Schimmels J; Tierney M
Nurs Outlook; 2023; 71(4):102004. PubMed ID: 37429154
[No Abstract] [Full Text] [Related]
18. Buprenorphine Initiation: Low-Dose Methods #457.
Ho JJ; Jones KF; Merlin JS; Sager Z; Childers J
J Palliat Med; 2023 Jun; 26(6):867-869. PubMed ID: 37276524
[No Abstract] [Full Text] [Related]
19. Novel forms of injectable buprenorphine and French model of opioid use disorder treatment.
Lapeyre-Mestre M
Therapie; 2020; 75(5):393-395. PubMed ID: 33039103
[No Abstract] [Full Text] [Related]
20. Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial.
Lintzeris N; Dunlop AJ; Haber PS; Lubman DI; Graham R; Hutchinson S; Arunogiri S; Hayes V; Hjelmström P; Svedberg A; Peterson S; Tiberg F
JAMA Netw Open; 2021 May; 4(5):e219041. PubMed ID: 33970256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
